Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Ra Capital Management
AddedFeb 13, 2024
UpdatedJul 16, 2026
Ra Capital Management

Ra Capital Management

Operating

RA Capital Management: Boston-based investment advisor specializing in life-sciences and drug development.

Location
Boston, MA, US
Founded
2001
Firm
Compare
Portfolio
Employees
Website

Investments

Memento Medicines
Memento Medicines
Series A

Total Raised

$93M

Rounds

1

Series A$93MJune 2026
SonoThera
SonoThera
Series B

Total Raised

$185.8M

Rounds

2

Series B$125MJune 2026
Astria Therapeutics
Astria Therapeutics
Public

Total Raised

$656.4M

Rounds

18

Post Ipo Equity$125MJanuary 2024
Vaxart
Vaxart
Public

Total Raised

$98.7M

Rounds

16

Post Ipo Equity$10MJanuary 2024
Claris Biotherapeutics
Claris Biotherapeutics

Total Raised

$101.5M

Rounds

3

Series A$57MJanuary 2024
Bicara Therapeutics
Bicara Therapeutics

Total Raised

$313M

Rounds

3

Series C$165MDecember 2023
AM Batteries
AM Batteries
Series B

Total Raised

$60.3M

Rounds

5

Series B$30MDecember 2023
Arvinas
Arvinas
Public

Total Raised

$461.6M

Rounds

5

Post Ipo Equity$350MNovember 2023
Forward Therapeutics
Forward Therapeutics

Total Raised

$50M

Rounds

2

Series A$50MNovember 2023
Rampart Bioscience
Rampart Bioscience

Total Raised

$85M

Rounds

1

Series A$85MOctober 2023
Aiolos Bio
Aiolos Bio
Acquired

Total Raised

$245M

Rounds

1

Series A$245MOctober 2023
Amplifier Therapeutics
Amplifier Therapeutics

Total Raised

$33.3M

Rounds

1

Series A$33.3MOctober 2023
Ventricle Health
Ventricle Health

Total Raised

$8M

Rounds

1

Seed$8MOctober 2023
Commons Clinic
Commons Clinic

Total Raised

$30.5M

Rounds

3

Series A$19.5MOctober 2023
SAB Biotherapeutics
SAB Biotherapeutics
Public

Total Raised

$186.3M

Rounds

8

Post Ipo Equity$130MOctober 2023
Adela
Adela

Total Raised

$108M

Rounds

2

Series A$48MSeptember 2023
Hyku
Hyku

Total Raised

$56M

Rounds

1

Seed$56MSeptember 2023
Vaxess Technologies
Vaxess Technologies

Total Raised

$74.9M

Rounds

19

Series Unknown$9MSeptember 2023
Mariana Oncology
Mariana Oncology

Total Raised

$250M

Rounds

2

Series B$175MSeptember 2023
Nimbus Therapeutics
Nimbus Therapeutics
Public

Total Raised

$637M

Rounds

9

Private Equity$210MSeptember 2023
Star Therapeutics
Star Therapeutics

Total Raised

$190M

Rounds

2

Series C$90MSeptember 2023
Sortera Alloys.
Sortera Alloys.

Total Raised

$52.5M

Rounds

4

Series C$30.5MAugust 2023
Superluminal Medicines
Superluminal Medicines

Total Raised

$33M

Rounds

1

Seed$33MAugust 2023
Excepgen
Excepgen

Total Raised

$4.2M

Rounds

3

Seed$4MAugust 2023
Abcuro
Abcuro

Total Raised

$214.8M

Rounds

5

Series B$155MAugust 2023